Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Investments (2018 - 2025)

Ascendis Pharma A (ASND) has disclosed Long-Term Investments for 8 consecutive years, with $37.9 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 161.0% to $37.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.9 million through Dec 2025, up 161.0% year-over-year, with the annual reading at $37.9 million for FY2025, 161.0% up from the prior year.
  • Long-Term Investments hit $37.9 million in Q4 2025 for Ascendis Pharma A, up from $14.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $43.9 million in Q4 2021 to a low of $6.1 million in Q4 2023.
  • Historically, Long-Term Investments has averaged $25.1 million across 5 years, with a median of $23.4 million in 2022.
  • Biggest five-year swings in Long-Term Investments: plummeted 73.85% in 2023 and later soared 161.0% in 2025.
  • Year by year, Long-Term Investments stood at $43.9 million in 2021, then tumbled by 46.66% to $23.4 million in 2022, then tumbled by 73.85% to $6.1 million in 2023, then surged by 137.11% to $14.5 million in 2024, then skyrocketed by 161.0% to $37.9 million in 2025.
  • Business Quant data shows Long-Term Investments for ASND at $37.9 million in Q4 2025, $14.5 million in Q4 2024, and $6.1 million in Q4 2023.